GFAP and depressive symptom measurement: In line with this hypothesis, an increase in plasma levels of markers of astrocytic activation, such as glial fibrillary acidic protein (GFAP) and S100β, are here shown to be significantly increased in patients with treatment-resistant depression when compared to healthy individuals [113].